文献速递甲状腺疾病

峡部甲状腺乳头状癌:全切/腺叶切除与峡部切除术的临床结局比较

Comparative Study of Clinical Outcomes for Total Thyroidectomy/Lobectomy and Isthmusectomy in Patients with Isthmic Papillary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2025-09-29

该回顾性队列纳入345例孤立性峡部PTC患者,经倾向评分匹配后比较全切/腺叶切除(TT/L)与峡部切除(I)各85例。两组ETE、多灶性、BRAF突变及中央区淋巴结转移风险无显著差异,随访期内均无复发或远处转移。峡部切除组主要并发症和左甲状腺素依赖显著更低,但新发甲状腺病灶更多。

要点

  • 峡部切除组暂时性/永久性低钙血症和暂时性声带麻痹发生率均低于TT/L组。
  • 峡部切除组左甲状腺素使用率、平均剂量及持续时间均显著低于TT/L组。
  • 峡部切除组新发甲状腺病灶发生率显著高于TT/L组(10.6% vs 1.3%)。

核心结论

  • 对于经过严格筛选的峡部局限性PTC患者,可考虑行峡部切除术。
  • 峡部切除术与TT/L在复发、远处转移及中央区淋巴结转移风险方面无显著差异。
  • 峡部切除术的主要并发症和左甲状腺素依赖显著低于TT/L,但新发甲状腺病灶更多。

研究设计与样本

  • 回顾性队列研究,纳入2013至2022年两家三级中心因孤立性峡部PTC行甲状腺切除术的345例患者。
  • 排除多灶伴腺叶受累、肿瘤>4 cm、疑似ETE、临床淋巴结阳性或侵袭性组织学亚型者。
  • 采用倾向评分匹配(PSM)形成TT/L组和I组各85例,共170例进行分析。

主要发现

  • 匹配后平均年龄48.2岁,平均肿瘤大小0.8 cm,微小癌占71.8%。
  • TT/L组与I组的ETE(65.3%)、多灶性(9.4%)、BRAF突变(75.3%)及桥本甲状腺炎(19.4%)无显著差异。
  • 中央区淋巴结转移风险分层无显著差异(高危:21.2% vs 27.1%,p=0.353)。
  • 中位随访4.3年,两组均无复发或远处转移;TT/L组中位随访更长(6.1年[IQR 4.0-8.5] vs 3.6年[IQR 2.1-4.9],p<0.001)。
  • TT/L组主要并发症更多:暂时性/永久性低钙血症(14.1%/1.2% vs 0%/0%),暂时性声带麻痹(3.5% vs 0%)。

关键数值与推荐

  • 左甲状腺素依赖:TT/L组使用率90.6% vs I组34.1%(p<0.001)。
  • 左甲状腺素平均剂量:TT/L组85.5±45.1 µg vs I组21.9±33.2 µg(p<0.001)。
  • 左甲状腺素使用持续时间:TT/L组5.2±3.1年 vs I组0.9±1.3年(p<0.001)。
  • 新发甲状腺病灶:TT/L组1.3% vs I组10.6%(p=0.039)。

临床怎么用

  • 对严格筛选的孤立性峡部PTC(无多灶、无ETE、无临床淋巴结阳性、非侵袭性亚型)可考虑峡部切除术。
  • 选择峡部切除术前应充分评估并告知新发甲状腺病灶风险较高,需长期随访监测。
  • 峡部切除术可显著降低暂时性/永久性低钙血症、声带麻痹及左甲状腺素依赖风险。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • TT/L组中位随访时间显著长于I组,可能影响复发和新发病灶的比较。
  • 样本量有限,结论需长期前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The optimal surgical extent for isthmus-confined papillary thyroid carcinoma (PTC) remains unclear. We aimed to evaluate the clinicopathological characteristics, surgical complications, and recurrence rates based on the extent of resection. Methods: This retrospective cohort study included 345 patients who underwent thyroidectomy for solitary isthmus-confined PTC at two affiliated tertiary centers from 2013 to 2022. Patients were excluded if they had multifocal PTC with lobar involvement, large tumors (>4 cm), suspected extrathyroidal extension (ETE), clinically positive lymph nodes (LNs), or aggressive histological subtypes. Clinicopathological features, surgical complication rates, and recurrence rates were compared among the total thyroidectomy (TT), lobectomy (L), and isthmusectomy (I) groups. This retrospective cohort study used propensity score matching (PSM), resulting in two groups of 85 patients: TT/L and I. Results: Among the 345 included patients, 89 underwent TT, 30 underwent L, and 226 underwent I. After PSM, 170 patients were analyzed. The mean age was 48.2 years, and the mean tumor size was 0.8 cm. Microcarcinoma accounted for 71.8% of cases. The rates of ETE (65.3%), multifocality (9.4%), BRAF mutation (75.3%), and Hashimoto's thyroiditis (19.4%) were observed without significant differences between the TT/L and I groups. Risk stratification for central LN metastasis showed no significant difference (high-risk: 21.2% vs. 27.1%, p = 0.353). No recurrence or distant metastasis was observed in either group during a median follow-up of 4.3 years. Median follow-up was longer in the TT/L group (6.1 years [interquartile range (IQR): 4.0-8.5] vs. 3.6 years [IQR: 2.1-4.9], p < 0.001). Major complications were more frequent in TT/L group: transient/permanent hypocalcemia (14.1%/1.2% vs. 0%/0%) and transient vocal cord palsy (3.5% vs. 0%). Levothyroxine dependency was significantly higher in the TT/L group in terms of usage (90.6% vs. 34.1%, p < 0.001), average administered dose (85.5 ± 45.1 µg vs. 21.9 ± 33.2 µg, p < 0.001), and duration (5.2 ± 3.1 years vs. 0.9 ± 1.3 years, p < 0.001). Newly noted thyroid lesions occurred more frequently in the I group (1.3% vs. 10.6%, p = 0.039). Conclusions: Isthmusectomy may be considered for carefully selected patients with isthmus-confined PTC. Validation in long-term prospective studies is warranted.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee S, Kim SJ, Choi JY, et al. Comparative Study of Clinical Outcomes for Total Thyroidectomy/Lobectomy and Isthmusectomy in Patients with Isthmic Papillary Thyroid Carcinoma. Thyroid. 2025. PMID: 41020703. doi:10.1177/10507256251382600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。